<DOC>
	<DOCNO>NCT02156362</DOCNO>
	<brief_summary>It generally estimate 5 % patient thyroid cancer develop distant metastasis , advanced stage disease presentation . Thirty per cent resistant radio iodine therapy call `` refractory '' . Their long term survival estimate less 10 % . The objective study identify factor associate poor outcome cohort patient advanced thyroid cancer follow 5 year . Anaplastic medullary thyroid carcinoma exclude .</brief_summary>
	<brief_title>Determination Pronostics Factors Advanced Thyroid Carcinoma ( pT3 pT4 M1 Diagnosis )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Man woman ≥ 18 year . Thyroid cancer differentiate follicular origin ( papillary , vesicular poorly differentiate carcinoma ) . TNM classification : stage pT3 ( ≥2 cm ) , pT4 M1 diagnosis . Patient post operative radioiodine therapy . Patient follow protocol . Patient consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Thyroid carcinoma</keyword>
	<keyword>predictive factor</keyword>
	<keyword>refractory</keyword>
	<keyword>Differentiated</keyword>
	<keyword>follicular origin</keyword>
</DOC>